CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Texas Sues Merck For Downplaying Dangers Of Vioxx





July 6, 2005
Texas Attorney General Greg Abbott has filed suit against one of the largest drug companies in the nation for misrepresenting the safety of the painkilling prescription drug Vioxx.

Related Stories

Researchers Claim Vioxx Safety Study Was Actually Marketing Plan
First Vioxx Judgment Overturned On Appeal
Merck Agrees to Pay $58 Million to Settle Vioxx Claims
Researchers Claim Merck Cooked Vioxx Data
Common Pain Relievers May Boost Muscle Mass
More Painkillers Can Cause More Pain
Merck Caves, Agrees To $4.85 Billion Vioxx Settlement
New York Sues Vioxx Maker over Drug’s Risks
Merck Wins Vioxx Case In Illinois
Judge Rules Out Vioxx "Super" Class Action
FDA Critic Blasts Merck's Vioxx Replacement
Merck Loses New Orleans Vioxx Case
Merck Wins Latest Vioxx Suit
Vioxx Study Authors Backtrack On Claim
Older Painkillers May Increase Heart Attack Risk
More about Vioxx
---
Other NSAIDs
Bextra
Celebrex
Dangers of Other Vioxx-Type Drugs
Vioxx Alternatives
Aleve Ingredient Seen as Health Risk

According to the lawsuit, Merck & Co. falsely touted the safety of the drug, knowing it caused a higher risk of heart attack and cardiovascular problems and at the same time, pushed to place Vioxx on the state’s Medicaid list for approved medicines.

Abbott alleges Merck aggressively marketed the drug to the medical community, and in doing so, willfully misrepresented its own studies and the concerns of physicians suggesting the drug may increase the risk of heart problems.

The Texas Medicaid program reimbursed pharmacists $56 million for Vioxx prescriptions they filled for patients over a five-year period.

The Attorney General is invoking a provision in state law that allows for that amount to be automatically tripled to $168 million, which Merck would have to pay to the state of Texas for acts of fraud.

“This is a prime example of a company’s drive for profit steamrolling its duty to be safe,” Abbott said. “Drug companies have an ethical, legal and professional responsibility to conduct meticulous clinical studies to ensure the safety and effectiveness of drugs for human consumption.

“Yet in this case,” Abbott said, “Merck took extreme measures to get this drug approved for widespread use, including for Medicaid patients, without the proper respect for good science and the concerns of peers.”

Merck, which began marketing Vioxx in 1999 after brief clinical trials, finally conceded the health concerns and voluntarily withdrew the product in September 2004.

The Attorney General’s lawsuit claims Merck’s costly promotional campaign aimed to convince consumers the drug was not only safe, but that they should demand it from their health care professionals for pain.

The company also allegedly tried to intimidate or threaten physicians and researchers who questioned the safety of Vioxx. The company even routinely misrepresented or concealed published evidence, including its own, showing possible harmful effects of the drug, the suit charges.

The Medicaid program reimbursed pharmacists for Vioxx prescriptions at the rate of about $1.94 per 25-milligram pill, the most commonly prescribed dosage. Pharmacists filled more than 700,000 prescriptions under the Medicaid program in these years, accounting for over 29 million pills.

If the facts about Vioxx had been known earlier, the Attorney General contends, physicians and their Medicaid patients would have chosen other nonsteroidal, anti-inflammatory agents like generic naproxen, which costs about $0.33 per daily equivalent dose.

According to the lawsuit, the company’s repeated failure to disclose the adverse effects of Vioxx, while offering it to the state’s Medicaid program as a safe painkiller, directly violates the Texas Medicaid Fraud Prevention Act.

The Attorney General requests restitution to the state of Texas, plus interest, for all Medicaid payments made to the company for Vioxx prescriptions, as well as civil penalties of up to $10,000 per violation of this law.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

September 6 2008

Recent Recalls & Safety Alerts



FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!


Knowledge is free.
Knowledge is power.







Back to the top |

Advertisement


Home | Complaint Form | News | Recalls | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds |


Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.